Clovis Oncology Inc is operative in the healthcare sector based in the United States. As a pharmaceutical manufacturer, it is focused on developing and commercializing anti-cancer agents. Its suite of product candidates includes Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor for the treatment of non-small cell lung cancer. Rucaparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP) that is in advanced clinical development for the treatment of ovarian cancer. The company's revenue primarily depends on the sale of Rucaparib in the United States market.
| Website: | www.clovisoncology.com |
| Email: | bburkart@clovisoncology.com |
| Main Phone: | +1 303 625-5000 |
| Address: | 5500 Flatiron Parkway |
| Address 2: | Suite 100 |
| State: | CO |
| City / Town: | Boulder |
| Country: | USA |
| Postal Code: | 80301 |
| Exchange: | NGS |
| CEO: | Patrick J. Mahaffy |
| Employees: | 468 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Gathering Data... Please wait Clovis Oncology Inc is operative in the healthcare sector based in the United States. As a pharmaceutical manufacturer, it is focused on developing and commercializing anti-cancer agents. Its suite of product candidates includes Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor for the treatment of non-small cell lung cancer. Rucaparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP) that is in advanced clinical development for the treatment of ovarian cancer. The company's revenue primarily depends on the sale of Rucaparib in the United States market.
| Website: | www.clovisoncology.com |
| Email: | bburkart@clovisoncology.com |
| Main Phone: | +1 303 625-5000 |
| Address: | 5500 Flatiron Parkway |
| Address 2: | Suite 100 |
| State: | CO |
| City / Town: | Boulder |
| Country: | USA |
| Postal Code: | 80301 |
| Exchange: | NGS |
| CEO: | Patrick J. Mahaffy |
| Employees: | 468 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
| Last Price 16.57 | Change $ -0.5 | Change % -2.93 | Tick N/A |
| Bid 16.56 | Bid Size 300.00 | Ask 16.59 | Ask Size 300.00 |
| Open 17.00 | High 17.20 | Low 16.32 | Prev Close 17.07 |
| Last Trade | Volume 431,026 | 52 Wk Hi 51.76 | 52 Wk Low 11.50 |
| Market Cap 878.3 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 53,004,845.00 | EPS (TTM) -7.17 | PE Ratio N/A | Exchange NGS |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 15 | 61 |
| Number of Buys | 7 | 24 |
| Number of Sells | 8 | 37 |
| Net Activity | -27459 | -429324 |
| Last 10 Buys | Shares |
|---|---|
| Edward J. McKinley | 1,000 |
| Edward J. McKinley | 1,000 |
| Edward J. McKinley | 1,000 |
| Edward J. McKinley | 1,000 |
| Erle T. Mast | 1,000 |
| Thorlef Spickschen | 1,000 |
| Gillian C. Ivers-Read | 1,000 |
| Edward J. McKinley | 1,000 |
| Paul H. Klingenstein | 1,000 |
| James C. Blair | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Thorlef Spickschen | 1,000 |
| Thorlef Spickschen | 1,000 |
| Thorlef Spickschen | 1,000 |
| Gillian C. Ivers-Read | 1,000 |
| Gillian C. Ivers-Read | 1,000 |
| Thorlef Spickschen | 1,000 |
| Gillian C. Ivers-Read | 1,000 |
| Thorlef Spickschen | 1,000 |
| Gillian C. Ivers-Read | 1,000 |
| Gillian C. Ivers-Read | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 97 | 97 | 97 | 97 |
| Low Target Price Estimate | 72 | 72 | 72 | 72 |
| Mean Target Price Estimate | 84.14 | 84.14 | 84.14 | 84.14 |
| Standard Deviation | 9.08 | 9.08 | 9.08 | 9.08 |
| Date of Most Recent Estimate | 06/05/18 | 05/09/18 | 05/09/18 | 06/05/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-08 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-08 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-08 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-08 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-06-07 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-01 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-01 |
| DEFA14A | Additional proxy soliciting materials - definitive | 2 | 2018-05-31 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-23 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 45 | 2018-05-09 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 6 | 7 | 7 | 8 |
| Moderate Buy | 1 | 1 | 2 | 2 |
| Hold | 2 | 2 | 2 | 2 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1.56 | 1.5 | 1.5 | 1.46 |
© 2019 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
